High Prevalence of Coronary Heart Disease in Type 2 Diabetic Patients with Non-alcoholic Fatty Liver Disease

Archives of Medical Research

Volumn 40, Issue 7, 2009, Pages 571-575

  Lu, Hongyun ^a   Zeng, Longyi ^a   Liang, Biao ^b   Shu, Xiaochun ^a   Xie, Danhong ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGDONG SECOND PROVINCIAL GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; ADULT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTHROPOMETRY; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHINESE; CHOLESTEROL BLOOD LEVEL; CLINICAL EXAMINATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DYSLIPIDEMIA; ECHOGRAPHY; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; RISK ASSESSMENT; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST HIP RATIO;

ANTHROPOMETRY; BODY MASS INDEX; CHINA; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FATTY LIVER; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 71649109525     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2009.07.009     Document Type: Article

References (28)

1. Adams L.A., Lymp J.F., St Sauver J., et al. The natural history of non-alcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129 (2005) 113-121
2. Farrell G.C., and Larter C.Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43 (2006) S99-S112
3. Bellentani S., Tiribelli C., Saccoccio G., et al. Prevalence of chronic liver disease in the general population of northern Italy: the Dionysos Study. Hepatology 20 (1994) 1442-1449
4. Bedogni G., Miglioli L., Masutti F., et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 42 (2005) 44-52
5. Akbar D.H., and Kawther A.H. Nonalcoholic fatty liver disease in Saudi type 2 diabetic subjects attending a medical outpatient clinic: prevalence and general characteristics. Diabetes Care 26 (2003) 3351-3352
6. Targher G., Bertolini L., Padovani R., et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 30 (2007) 1212-1218
7. Belfort R., Harrison S.A., Brown K., et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355 (2006) 2297-2307
8. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 346 (2002) 1221-1231
9. Ruhl C.E., and Everhart J.E. Epidemiology of nonalcoholic fatty liver. Clin Liver Dis 8 (2004) 501-519
10. Musso G., Gambino R., Bo S., et al. Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with Adult Treatment Panel III criteria in nonobese nondiabetic subjects. Diabetes Care 31 (2008) 562-568
11. Younossi Z.M., Gramlich T., Matteoni C.A., et al. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol 2 (2004) 262-265
12. Cortez-Pinto H., Camilo M.E., Baptista A., et al. Non-alcoholic fatty liver: another feature of the metabolic syndrome?. Clin Nutr 18 (1999) 353-358
13. Marchesini G., Moscatiello S., Di Domizio S., et al. Obesity-associated liver disease. J Clin Endocrinol Metab 93 (2008) S74-S80
14. Marchesini G., Marzocchi R., Agostini F., et al. Non-alcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol 16 (2005) 421-427
15. Targher G., and Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 191 (2007) 235-240
16. Ioannou G.N., Weiss N.S., Boyko E.J., et al. Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology 43 (2006) 1145-1151
17. Schindhelm R.K., Dekker J.M., Nijpels G., et al. Alanine aminotransferase predicts coronary heart disease events: a 10 year follow-up of the Hoorn Study. Atherosclerosis 191 (2007) 391-396
18. Fatty Liver and Alcoholic Liver Disease Study Group of Chinese Liver Disease Association. Diagnostic criteria of nonalcoholic fatty liver disease. Zhonghua Gan Zang Bing Za Zhi 14 (2006) 161-163
19. Targher G., Bertolini L., Padovani R., et al. Increased prevalence of cardiovascular disease in type 2 diabetic patients with non-alcoholic fatty liver disease. Diabet Med 23 (2006) 403-409
20. Targher G., Bertolini L., Poli F., et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 54 (2005) 3541-3546
21. Bruno G., Merletti F., Biggeri A., et al. Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. Diabetes Care 27 (2004) 2689-2694
22. Ford E.S. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 173 (2004) 309-314
23. Kotronen A., Juurinen L., Hakkarainen A., et al. Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. Diabetes Care 31 (2008) 165-169
24. Sattar N., Scherbakova O., Ford I., et al. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. Diabetes 53 (2004) 2855-2860
25. Hanley A.J., Williams K., Festa A., et al. Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes 54 (2005) 3140-3147
26. Schindhelm R.K., Dekker J.M., Nijpels G., et al. Alanine aminotransferase and the 6 year risk of the metabolic syndrome in Caucasian men and women: the Hoorn Study. Diabet Med 24 (2007) 430-435
27. Adibi P., Sadeghi M., Mahsa M., et al. Prediction of coronary atherosclerotic disease with liver transaminase level. Liver Int 27 (2007) 895-900
28. Day C.P. Non-alcoholic fatty liver disease: current concepts and management strategies. Clin Med 6 (2006) 19-25